Dr. Robert W. Given, M.D.

Medicare patients and services

Medicare patients, 2024

1,681

Services billed

36,903

Patients’ average age

76

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 13 companies reported 95 payments worth $37,134 in total to this clinician.

What the payments were for

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Virginia →

Industry-funded research

Named as a principal investigator on 10 industry-funded studies in 2025, from 8 companies. The companies reported $1,265,090 in research payments for these studies, mostly to the institutions running them.

• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Pfizer Inc.
• A Phase 3, Open-label, Randomized, Prospective Study of Apalutamide Monotherapy Versus Apalutamide Plus Androgen Deprivation Therapy (ADT) in Participants Newly Diagnosed with Metastatic Castration-Sensitive Prostate …
  Janssen Research & Development, LLC
• Metastatic Castrate-Resistant Prostate Cancer Subjects Treated With PROVENGE® + One Infusion of Sipuleucel-T
  Dendreon Pharmaceuticals LLC · Recruiting · NCT06134232
• A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
  Sumitomo Pharma America, Inc. · Completed · NCT05467176
• A phase 3 randomized efficacy and safety study of enzalutamide plus leuprolide enzalutamide monotherapy and placebo plus leuprolide in men with highrisk nonmetastatic prostate cancer progressing after definitive therapy
  Medivation LLC.
• A Randomized Double blind Placebo controlled Phase 3 Study of Apalutamide in Subjects with High risk Localized or Locally Advanced Prostate Cancer Who are Candidates for Radical Prostatectomy
  Janssen Research & Development, LLC
• A Phase 3, Randomized, Double-blind Trial of Pembrolizumab MK-3475 Plus Enzalutamide Plus ADT Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer mHSPC KEYNOTE-991
  Merck Sharp & Dohme LLC
• BAY 1841788, Darolutamide Observational Study in non-metastatic castration-resistant prostate cancer patients
  Bayer HealthCare Pharmaceuticals Inc.
• Randomized Study to Evaluate MACE in Patients With Prostate Cancer Treated With Relugolix or Leuprolide Acetate
  Sumitomo Pharma America, Inc. · Completed · NCT05605964
• A Phase 2 Open-label Extension Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
  Astellas Pharma Global Development

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Urology clinicians in Virginia Beach

• Nima Baradaran, M.D.
• Alexander Birk, MD
• Victor M. Brugh, MD
• Kevin J. Chua, MD
• Jessica M. Delong, M.D.
• Johnathan A. Drevik, MD
• Edwin S. Epstein, MD
• Gregg R. Eure, M.D.